New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
08:05 EDTJNJJanssen-Cilag says Olysio receives marketing authorization in the EU
Janssen-Cilag International NV announced that its next generation protease inhibitor OLYSIO has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C, in combination with other medicinal products.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:27 EDTJNJJohnson & Johnson drug business likely to remain resilient, says Wells Fargo
Subscribe for More Information
July 29, 2015
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use